{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fpce.simplecast.com%2Fepisodes%2Fparp-inhibitors-in-mcrpc-l9wMpTOb","width":444,"version":"1.0","type":"rich","title":"A Nursing Perspective on PARP Inhibitors in Prostate Cancer","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/06299887-ad15-4388-9852-e133fc97cac7/pce-podcast-parp-inhibitors-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/ad81d0c0-f6a1-449b-ac36-615d53a2bf85\" height=\"200\" width=\"100%\" title=\"A Nursing Perspective on PARP Inhibitors in Prostate Cancer\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"The treatment landscape of metastatic castrate-resistant prostate cancer (mCRPC) is continually evolving. In this podcast, an advanced practice provider discusses recent evidence on PARP inhibitors for mCRPC and how they incorporate these data into clinical practice. \n\nTopics include the role of PARP inhibitors for mCRPC with mutations in homologous recombination repair genes, testing for BRCA1/2 and other homologous recombination repair mutations, approved indications for olaparib and rucaparib, managing adverse events with approved PARP inhibitors, and a look at the future of PARP inhibition in mCRPC. "}